Three-Drug Combination for IDH1-Mutated AML: Encouraging Results in Elderly Patients #AML | EHA 2026

Dr. Jennifer Marvin-Peek from MD Anderson Cancer Center presents results from a phase 1b/2 trial combining three drugs for IDH1-mutated acute myeloid leukemia (AML) in elderly and unfit patients.

ABOUT IDH1-MUTATED AML:
IDH1 mutations occur in about 7-8% of AML patients, more commonly in older adults. These patients often can't receive intensive chemotherapy due to age or health issues.

PREVIOUS TREATMENT OPTIONS:
- Ivosidenib alone or with azacitidine: 50-67% remission, lasting 1-2.5 years
- Azacitidine with another targeted drug: Similar results

THE NEW APPROACH:
Combining all THREE drugs together:
- Azacitidine
- Venetoclax
- Ivosidenib

IMPRESSIVE RESULTS:
- 40 patients enrolled with newly diagnosed AML
- 38/40 responded to treatment
- 37/40 achieved complete remission (92.5%)
- About half went on to transplant
- 3-year follow-up: 80% still living
- Well tolerated with no additive side effects

WHY IT MATTERS:
For elderly and unfit AML patients with IDH1 mutations, this combination offers much higher remission rates and better survival than current standard treatments.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction
0:12 The Trial at MD Anderson
0:19 Patient Population (Elderly/Unfit)
0:27 IDH1-Mutated AML Overview
0:35 How Common is IDH1 Mutation?
0:59 Current Approved Treatments
1:08 Ivosidenib Options
1:30 Current Remission Rates
1:49 The Three-Drug Combination
2:06 Trial Details & Enrollment
2:23 Results: Response Rates
2:32 Complete Remission Achievement
2:39 Long-Term Survival (3 Years)
2:48 Tolerability & Side Effects
3:04 Why This Is Encouraging

#AML #IDH1Mutation #ClinicalTrial #NewTreatment #Elderly